AKT1 and differentiated thyroid carcinoma: As widely known, the large majority of DTCs are characterized by mutually exclusive driver events, either point mutations or gene rearrangements, involved in the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathway.1, 2, 3 In particular, nonoverlapping mutations of BRAF (60%), NRAS (4%), HRAS (1.5%), and KRAS (0.3%) genes are found in conventional papillary thyroid carcinoma (PTC)—that is, those PTCs that grow making papillae—including classical and tall cell subtypes.1, 2, 3